Skip to main content
. 2019 Sep 16;20(18):4575. doi: 10.3390/ijms20184575

Figure 7.

Figure 7

Hsp90 inhibitors compound 5 chemosensitizes MDR cancer cells to doxorubicin (DOX) and paclitaxel (PTX). (a) Cell growth inhibition by DOX in single and combination treatments with Hsp90 inhibitors in MDR NCI-H460/R cells. (b) Synergistic type of interaction between 5 and DOX. (c) Cell growth inhibition by PTX in single and combination treatments with Hsp90 inhibitors in MDR DLD1-TxR cells. (d) Synergistic type of interaction between 5 and PTX. The results are expressed as mean ± SEM. Statistical significance to DOX or PTX alone from three experiments: p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). CI values below 1 depict synergistic effect.